Graphite Bio
South San Francisco
CA
United States
55 articles about Graphite Bio
-
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
3/8/2024
Graphite Bio, Inc. announced that its Board of Directors has declared a special dividend in connection with the previously announced merger with Lenz Therapeutics, Inc. pursuant to the Agreement and Plan of Merger, dated November 14, 2023.
-
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
11/15/2023
LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
-
Graphite Bio Announces Departure of Chief Financial Officer
6/23/2023
Graphite Bio, Inc. (Nasdaq: GRPH) today announced that Alethia Young, the Company’s Chief Financial Officer, will step down from her position to pursue other opportunities.
-
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
3/20/2023
Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results.
-
Graphite Bio is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset, and shaving off about 50% of its workforce.
-
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
2/22/2023
Graphite Bio, Inc. announced that it has completed a review of its business, including the status of its programs, resources and capabilities.
-
Graphite Bio announced it is voluntarily pausing the Phase I/II study of its lead candidate nula-cel in sickle cell disease.
-
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
1/5/2023
Graphite Bio, Inc. announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel for sickle cell disease due to a serious adverse event in the first patient dosed with nula-cel, and the company’s conclusion that the event is likely related to study treatment.
-
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
12/11/2022
Graphite Bio, Inc. presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel, an investigational gene-edited therapy for sickle cell disease.
-
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
11/21/2022
Graphite Bio, Inc. today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET.
-
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
11/9/2022
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and third quarter 2022 financial results.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
While worthy advances have recently been made in sickle cell disease, companies such as Graphite Bio, bluebird bio, Vertex Pharmaceuticals and Editas Medicine have loftier ambitions.
-
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
10/11/2022
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention.
-
Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer.
-
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
8/11/2022
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today reported recent business progress and second quarter 2022 financial results.
-
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
8/11/2022
Graphite Bio, Inc. today announced that the first patient has been dosed with GPH101, now called nulabeglogene autogedtemcel (nula-cel), in the company’s Phase 1/2 CEDAR trial in people with sickle cell disease (SCD).
-
Women of color continue to be trailblazers in the life science industry, proving that they can be just as, if not more, successful than their peers - even if it isn’t always easy.
-
Graphite Bio Announces Participation in Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Graphite Bio, Inc. announced that members of the management team will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4 p.m. ET.
-
The ASGCT's 25th Annual Meeting features the latest scientific research in genetics and cellular therapies. Read on for highlights from the meeting.